Section Editor: Bibianna Purgina, MD FRCPC
October 12, 2026
An inflammatory myofibroblastic tumor, often shortened to IMT, is a rare tumor made of long, thin cells called myofibroblasts, mixed with many immune cells. It can start almost anywhere in the body, but it is most often found in the lungs and in the abdomen and pelvis, including the bladder. It is most common in children and young adults, although it can occur at any age.
Inflammatory myofibroblastic tumor sits between a benign tumor and a cancer. It often recurs in the same place after removal, but it rarely spreads to other parts of the body. Many of these tumors are driven by a change in a gene called ALK, which can be treated with targeted drugs when surgery is not possible.
This article explains how doctors diagnose inflammatory myofibroblastic tumor and what your pathology report says about the tumor type, margins, and gene changes. It also explains what these findings mean for treatment and follow-up.
Inflammatory myofibroblastic tumor can occur at any age, but it is found most often in children, teenagers, and young adults. It is one of the more common tumors of the lung in children. In adults, it most often occurs in the abdomen and pelvis, including the bladder, and in the lungs.
The cause of inflammatory myofibroblastic tumor is not fully understood. In most of these tumors, the tumor cells carry a gene change in which part of one gene has joined with part of another gene. This change, called a fusion, makes the cells grow when they should not. The fusion occurs only in tumor cells and is not inherited, so it does not put family members at risk.
The ALK gene is involved in more than half of these tumors. Other genes, such as ROS1, NTRK3, and RET, are involved in smaller numbers. Altogether, modern tests can detect this type of fusion in most inflammatory myofibroblastic tumors.
The symptoms of inflammatory myofibroblastic tumor depend on where the tumor starts. An abdominal tumor may cause pain, swelling, or a blocked bowel. A lung tumor may cause a cough, chest pain, or shortness of breath. A bladder tumor usually causes blood in the urine.
Some people also have general symptoms, such as fever, weight loss, or tiredness. Blood tests may show anemia or signs of inflammation. These general symptoms often go away after the tumor is removed. Some tumors cause no symptoms and are found on a scan done for another reason.
A pathologist diagnoses inflammatory myofibroblastic tumor after examining a tumor sample under a microscope. The sample may be a small biopsy or the whole tumor removed during surgery. Before the biopsy, scans such as CT or MRI are used to see the size of the tumor and whether it has grown into nearby organs.
Under the microscope, inflammatory myofibroblastic tumor consists of spindle cells, long, thin cells with tapering ends. These cells are mixed with many immune cells, especially plasma cells and lymphocytes. The tissue around the cells can look loose and watery (myxoid), or dense and scarred. The tumor cells usually do not look as abnormal as sarcomas
Because inflammatory myofibroblastic tumor can resemble several other tumors and inflammatory conditions, pathologists usually perform additional tests on the tissue. The next section describes these tests.
Immunohistochemistry uses special stains to show which proteins cells in an inflammatory myofibroblastic tumor make. The results help the pathologist confirm that the cells are myofibroblasts and rule out other tumors that can look similar. The stains used and how results are worded vary between laboratories. Results you may see in your report include:
Not every case needs every stain. When the stains do not settle the diagnosis, a molecular test may be performed to look for the gene fusion, as described in the biomarker section below.
The World Health Organization (WHO) classification of soft tissue tumors, 5th edition (2020), recognizes inflammatory myofibroblastic tumor and a less common type called epithelioid inflammatory myofibroblastic sarcoma. The two types behave very differently, so your report will name the type if it can be determined.
In the urinary tract, a closely related growth called pseudosarcomatous myofibroblastic proliferation is grouped with inflammatory myofibroblastic tumor in the WHO classification of urinary tumors, 5th edition (2022). Your report may use either name for a bladder tumor.
Inflammatory myofibroblastic tumor is not given a grade. The grading systems used for sarcomas do not predict how this tumor will behave, so your report will not include a grade number, and this is expected. Instead, the tumor type, location, size, and whether it was removed completely provide the most useful information about how it is likely to behave.
The size of an inflammatory myofibroblastic tumor is measured after removal and reported in centimeters. Tumors in the abdomen and pelvis are often larger than tumors in other sites when they are found. Larger tumors are harder to remove completely and more likely to recur. Size measured on a small biopsy does not reflect the size of the whole tumor.
Inflammatory myofibroblastic tumor can grow into surrounding tissues and organs as it enlarges. This spread into nearby structures is called tumor extension. The pathologist examines all the tissue removed to see whether tumor cells have grown into nearby fat, muscle, or organs. Extension into nearby organs can make complete removal harder and may change the treatment your team recommends.
When an inflammatory myofibroblastic tumor is removed, the pathologist examines the cut edges of the tissue, called the margins. Because this tumor often grows back in the same place, the margins are one of the most important findings in your report.
Biomarker testing for inflammatory myofibroblastic tumor looks for the gene fusion that drives tumor growth. Finding the fusion can confirm the diagnosis, and it can make a person eligible for a targeted drug if the tumor cannot be removed or comes back. Clinicians test tumor tissue with fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS).
ALK is a gene that makes a protein involved in cell growth. In inflammatory myofibroblastic tumor, part of the ALK gene is often joined to another gene, which turns the protein on all the time. ALK fusions are the most common gene change in this tumor.
ROS1 is a gene that is similar to ALK. A ROS1 fusion is found in a small number of inflammatory myofibroblastic tumors, usually those that are ALK-negative.
The NTRK genes make proteins involved in cell growth. An NTRK3 fusion is found in a small number of inflammatory myofibroblastic tumors.
RET is another gene involved in cell growth. A RET fusion is found in only a very small number of inflammatory myofibroblastic tumors.
Our article on NTRK fusions in cancer explains how fusion testing works. For more information on tumor testing, visit our Biomarkers and Genetic Testing section.
The prognosis for inflammatory myofibroblastic tumor is generally good, especially when the tumor is removed completely. Death from this tumor is uncommon. The main risk is that the tumor grows back in the same place.
These numbers are averages for large groups of people and don’t predict what will happen to you. Features in your report that are linked to a higher chance of the tumor growing back or spreading include:
After a diagnosis of inflammatory myofibroblastic tumor, your care team uses the type of tumor, the margins, and other findings in your report to plan treatment. The team may include a surgeon, a medical oncologist, and, for children, a pediatric oncologist. Treatment depends mainly on whether the whole tumor can be removed safely.
Approval and access to these drugs differ by country, and your care team can explain what applies where you live.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name